Top Markets
#1 MowCat MowCat +48.96%
#2 Audiera Audiera +28.09%
#3 Velvet Velvet +27.19%
#4 Bermuda Shorts Bermuda Shorts +24.66%
#5 Biconomy Biconomy +22.49%
#6 aPriori aPriori +22.35%
#7 Quack AI Quack AI +21.37%
#8 Derive Derive +19.47%
#9 SkyAI SkyAI +14.21%
#10 Geodnet Geodnet +12.98%
Coin of the day
MowCat MowCat
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Graybug Vision, Inc. Graybug Vision, Inc.

Graybug Vision, Inc.

GRAY
Clasificación en acciones #35305
Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical... Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.
Precio por acción
$2.70
Última sincronización: 2023-05-17
Capitalización bursátil
$4.13M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Graybug Vision, Inc. (GRAY)

Categoría

Healthcare
Ganancias de Graybug Vision, Inc. (GRAY)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Graybug Vision, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Graybug Vision, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE